logo-loader
RNS
Kromek Group PLC

Kromek receives $1.4m Advanced Imaging order

RNS Number : 8685B
Kromek Group PLC
05 November 2026
 

5 November 2026

 

Kromek Group plc 

(“Kromek” or the “Group”) 

 

Kromek receives $1.4m Advanced Imaging order

 

Kromek Group plc (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, is pleased to announce that it has received a follow-on $1.4m order from an existing OEM customer in the Advanced Imaging division.

 

The order is for the supply of CZT-based detector components for the customer’s medical systems. The Group will commence delivery immediately, which is expected to be completed over the next 12 months.

 

Arnab Basu, CEO of Kromek, said: “We are pleased to have received this additional order from an existing OEM customer. It reflects the repeat nature of business in our Advanced Imaging division, with a steady flow of follow-on orders once our detectors are designed into a system. Delivery of this order will contribute to our growth in the current year as well as provide visibility into the next financial year. We look forward to updating the market on further progress within Advanced Imaging.”

 

 

For further information, please contact: 

  

Investor questions on this announcement

 

We encourage all investors to share questions on this announcement via our investor hub

               https://investors.kromek.com/link/egL70r

 

 

Kromek Group plc 

 

Arnab Basu, CEO 

Claire Burgess, CFO 

+44 (0)1740 626 060 

 

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)  

  

Geoff Nash/Giles Balleny/Seamus Fricker – Corporate Finance 

Michael Johnson – Sales

+44 (0)20 7220 0500 

 

 

 

Gracechurch Group (Financial PR) 

 

Harry Chathli/Claire Norbury 

+44 (0)20 4582 3500 

 

 

Engage with the Kromek management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our interactive investor
hub here: https://investors.kromek.com/

 

Subscribe to our news alert service: https://investors.kromek.com/auth/signup

 

Kromek Group plc 

 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

 

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

 

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

 

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIBMTMTBMTTF
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read